Patents by Inventor Oliver Nayler

Oliver Nayler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20210401811
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 30, 2021
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Patrick BROSSARD, Jasper DINGEMANSE, Oliver NAYLER, Michael SCHERZ, Beat STEINER
  • Dosing regimen for a selective S1Pagonist
    Patent number: 10660880
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: May 26, 2020
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • Dosing regimen for a selective S1Preceptor agonist
    Patent number: 10251867
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: April 9, 2019
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase
    Patent number: 10189839
    Abstract: The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: January 29, 2019
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Daniel Bur, Corinna Grisostomi, Oliver Nayler, Lubos Remen, Magali Vercauteren, Richard Welford
  • Tricyclic piperidine compounds
    Patent number: 9765092
    Abstract: The present invention relates to compounds of the formula (I) wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: September 19, 2017
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Daniel Bur, Corinna Grisostomi, Oliver Nayler, Lubos Remen, Magali Vercauteren, Richard Welford
  • Pyridin-4-yl derivatives
    Patent number: 9617250
    Abstract: The invention relates to compounds of the Formula (I), Formula (I) wherein R1 and R2 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 11, 2017
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Cyrille Lescop, Oliver Nayler, Beat Steiner
  • TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE
    Publication number: 20160289232
    Abstract: The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.
    Type: Application
    Filed: November 18, 2014
    Publication date: October 6, 2016
    Inventors: Daniel BUR, Corinna GRISOSTOMI, Oliver NAYLER, Lubos REMEN, Magali VERCAUTEREN, Richard WELFORD
  • TRICYCLIC PIPERIDINE COMPOUNDS
    Publication number: 20160272655
    Abstract: The present invention relates to compounds of the formula (I) wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.
    Type: Application
    Filed: November 18, 2014
    Publication date: September 22, 2016
    Inventors: Daniel BUR, Corinna GRISOSTOMI, Oliver NAYLER, Lubos REMEN, Magali VERCAUTEREN, Richard WELFORD
  • PYRIDIN-4-YL DERIVATIVES
    Publication number: 20160031866
    Abstract: The invention relates to compounds of the Formula (I), Formula (I) wherein R1 and R2 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Cyrille Lescop, Oliver Nayler, Beat Steiner
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20150265580
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: June 5, 2015
    Publication date: September 24, 2015
    Inventors: PATRICK BROSSARD, JASPER DINGEMANSE, OLIVER NAYLER, MICHAEL SCHERZ, BEAT STEINER
  • 2-methoxy-pyridin-4-yl-derivatives
    Patent number: 9133179
    Abstract: The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: September 15, 2015
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Keith Morrison, Claus Mueller, Oliver Nayler, Beat Steiner
  • Thiazolidin-4-one-derivatives
    Patent number: 9000018
    Abstract: The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: April 7, 2015
    Assignee: Actelion Pharmaceuticals, Ltd
    Inventors: Christoph Binkert, Martin Bolli, Boris Mathys, Claus Mueller, Michael Scherz, Oliver Nayler
  • DOSING REGIMEN FOR A SELECTIVE S1P1 AGONIST
    Publication number: 20140316140
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: PATRICK BROSSARD, Jasper DINGEMANSE, Oliver NAYLER, Michael SCHERZ, Beat STEINER
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20140315964
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: July 2, 2014
    Publication date: October 23, 2014
    Inventors: PATRICK BROSSARD, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST
    Publication number: 20140303217
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Inventors: Patrick BROSSARD, Jasper DINGEMANSE, Oliver NAYLER, Michael SCHERZ, Beat STEINER
  • Dosing regimen for a selective S1P1 receptor agonist
    Patent number: 8785484
    Abstract: The present invention relates to a dosing regimen for a selective S1P1 receptor agonist, whereby the selective S1P1 receptor agonist is administered to a subject in such a way that during the initial treatment phase the selective S1P1 receptor agonist is administered at a dose which induces desensitization of the heart wherein said dose is below the target dose, and at a dosing frequency that sustains desensitization of the heart, until no further acute heart rate reduction occurs, followed by dose up-titration to the target dose of the selective S1P1 receptor agonist.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: July 22, 2014
    Assignee: Actelion Pharmaceuticals Ltd
    Inventors: Patrick Brossard, Jasper Dingemanse, Oliver Nayler, Michael Scherz, Beat Steiner
  • Pyridine derivatives
    Patent number: 8697732
    Abstract: The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: April 15, 2014
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Martin Bolli, David Lehmann, Boris Mathys, Claus Mueller, Oliver Nayler, Beat Steiner, Jörg Velker
  • Pyridin-4-yl derivatives
    Patent number: 8658675
    Abstract: The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, and R4 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: February 25, 2014
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Keith Morrison, Claus Mueller, Oliver Nayler, Beat Steiner
  • Pyridine derivatives as S1P1/EDG1 receptor modulators
    Patent number: 8598208
    Abstract: The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: December 3, 2013
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Martin Bolli, Cyrille Lescop, Boris Mathys, Claus Mueller, Oliver Nayler, Beat Steiner, Jorg Velker
  • Thiazolidin-4-one derivatives
    Patent number: RE45174
    Abstract: The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: September 30, 2014
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Christoph Binkert, Martin Bolli, Boris Mathys, Claus Mueller, Michael Scherz, Oliver Nayler